Clinical trials: Lymphoma, Diffuse Large-Cell
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238368
- Testing
- filgrastim, rituximab, busulfan
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT01719250
- Testing
- Buparlisib, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Phase I/II trial to study the effectiveness of combining yttrium Y 90 ibritumomab tiuxetan with rituximab in treating patients who have localized or recurrent lymphoproliferative disorder after an organ transplant.
- Conditions
- Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage III Adult Burkitt Lymphoma
- Trial name
- NCT00064246
- Testing
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT03837873
- Testing
- Rituximab, Etoposide, Vincristine
- Where
- 6 sites in China
- Volunteers
- 118 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003113
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, Large Cell, Diffuse
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT…
- Trial name
- ZBEAM2 (NCT00689169)
- Testing
- ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan), ASCT, Rituximab
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B Cell Lymphoma
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
It is expected that addition of anti-CD20 antibody - ofatumumab would enhance the activity of the etoposide+ifosphamide with mesna+cytarabine+methotrexate+lenograstim or filgrastim (IVAC) regimen.
- Trial name
- PLRG8 (NCT01481272)
- Testing
- Ofatumumab, Etoposide, Ifosfamid
- Where
- 8 sites in Poland
- Volunteers
- 77 people
- Sponsor
- Polish Lymphoma Research Group
Non-Hodgkin Lymphoma
A Rollover Study of CC-122
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002…
- Trial name
- NCT05688475
- Testing
- CC-122, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00107380
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 86 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Arginine methylation mediated by protein arginine methyl-transferases (PRMTs) is an important post-translational modification of proteins involved in a diverse range of cellular processes.
- Trial name
- NCT03666988
- Testing
- GSK3368715
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
The goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called atlacabtagene autoleucel is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Non-Hodgkin Lymphoma
- Trial name
- ENABLE-2 (NCT06486051)
- Testing
- Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells
- Where
- 3 sites in New Zealand
- Volunteers
- 60 people
- Sponsor
- Malaghan Institute of Medical Research
Lymphoma, Large B-Cell, Diffuse
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP regimen) has been the first-line chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02428751
- Testing
- Pegylated liposomal doxorubicin, Doxorubicin, Rituximab
- Where
- 7 sites in China
- Volunteers
- 216 people
- Sponsor
- Wenqi Jiang
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse
Yoga Fatigue Study
Fatigue is a major problem in children, adolescents and adults receiving intensive chemotherapy for cancer and in patients undergoing hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV
- Trial name
- NCT02134782
- Testing
- Individualized Yoga Intervention Group, iPad Activity Control Group
- Where
- 3 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- The Hospital for Sick Children
Leukemia, Lymphoma
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
RATIONALE: Valproic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also help cancer cells become more like normal cells, and grow and spread more slowly.
- Trial name
- NCT01016990
- Testing
- valproic acid, western blotting, laboratory biomarker analysis
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Auxilio Mutuo Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Diffuse Large Cell Lymphoma, Lymphoma
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and…
- Trial name
- NCT00591630
- Testing
- Zevalin, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center